medscape.com
Cure8 news brief
Why This Matters
Perianal fistulas cause significant morbidity and often need both medical and surgical treatments. Newer drug options and updated guideline support earlier use of advanced therapies, which may improve healing and reduce ongoing fistula complications.
Who Should Pay Attention
Adults with Crohn's disease and perianal fistulas, gastroenterologists, colorectal surgeons, and multidisciplinary IBD care teams.
Study Snapshot
Story typeResearch news
Evidence typeClinical study
Source depthFull source text
What To Know
Perianal fistulizing Crohn's is complex and often needs both medical and surgical approaches. Anti‑TNF drugs (infliximab, adalimumab) remain first‑line for many clinicians, with attention to higher therapeutic drug levels for better healing.
Newer therapies discussed include IL‑23 blockade (guselkumab, with phase 3 FUZION data cited) and JAK inhibition (upadacitinib) as options particularly for patients who fail or cannot tolerate anti‑TNF therapy.
The article also stresses pelvic MRI or endoanal ultrasound for anatomy and risk stratification, timely drainage of sepsis, and seton use and multidisciplinary care.
Practical points: combining a biologic with antibiotics can be recommended for induction in some patients without abscess; simple low fistulas without rectal inflammation may sometimes be managed surgically (eg, fistulotomy), but most patients with perianal fistulas are considered for early advanced therapy.
Keep In Mind
The piece is an expert review summarizing guideline recommendations and recent trial data (eg, FUZION guselkumab results) rather than reporting new primary trial findings. Treatment choices should be individualized and discussed with a clinician.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationmedscape.com
PublisherMedscape
AuthorsDavid A. Schwartz, MD
Indexed viaBing News
Source typeWeb article
PublishedOct 7, 2026, 5:00 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Perianal Fistulizing Crohn's: New Evidence, Practical Care - Medscape
Perianal fistulizing Crohn's often causes significant symptoms and requires both medical and surgical approaches. Newer biologics and JAK inhibitors expand treatment options and guidelines increasingly support earlier...
Beyond class switching in multi-refractory inflammatory bowel disease: Nine case reports and review of literature
For people with multi-refractory Crohn’s disease or ulcerative colitis, adding a JAK inhibitor to an existing biologic (advanced combination therapy) may convert partial responses into deeper remission in selected cases,...
Escalating Crohn’s Care: The Case for Dual Therapy
Researchers and clinicians are increasingly studying combinations of IBD drugs because single‑drug remission rates have plateaued; dual therapy may improve outcomes for patients who have failed prior treatments.